Losartan potassium
Based on 60 publication(s) in Google Scholar
Losartan potassium (DuP-753 potassium) is an angiotensin II receptor type 1 (AT1) antagonist, competing with the binding of angiotensin II to AT1 with an IC50 of 20 nM.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.98%
- CAS No.: 124750-99-8
- Formule: C22H22ClKN6O
- Masse moléculaire:461.00
-
Stockage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-B0368
CaptoprilACE Inhibitor -
HY-13948
Angiotensin II humanVasoconstrictor -
HY-13955
TelmisartanAngiotensin II Type 1 Receptor -
HY-18204
ValsartanAngiotensin II Receptor Antagonist -
HY-B0205
CandesartanAngiotensin II AT1-Receptor Blocker -
HY-B0202
IrbesartanAT1 Receptor Blocker -
HY-10219
RapamycinmTOR Inhibitor -
HY-17512AR
Losartan potassium (Standard)AT1 Antagonist -
HY-12405
CGP-42112AT2 Agonist -
HY-B0215
AcetylcysteineMucolytic Agent -
HY-B0589
AtorvastatinHMG-CoA Reductase Inhibitor -
HY-11106
Nintedanib esylatePDGFR/VEGFR/FGFR Inhibitor
Publications Citing Use of MedChemExpress (MCE) Losartan potassium
More- Nat Commun. 2025 Nov 25;16(1):10430. [Abstract]
- Adv Sci (Weinh). 2025 Jan;12(4):e2410360. [Abstract]
- Mol Biomed. 2025 Feb 11;6(1):10. [Abstract]
- Cell Death Dis. 2020 May 22;11(5):390. [Abstract]
- J Immunother Cancer. 2026 Mar 25;14(3):e012426. [Abstract]
- J Immunother Cancer. 2024 Sep 6;12(9):e009327. [Abstract]
- Phytomedicine. 2025 Jan:136:156314. [Abstract]
- Phytomedicine. 2023 Apr:112:154700. [Abstract]
- Phytomedicine. 2022 Mar 21;100:154067. [Abstract]
- Adv Healthc Mater. 2025 Apr;14(11):e2500176. [Abstract]
- J Transl Med. 2024 Jan 5;22(1):26. [Abstract]
- Oncogene. 2023 Apr;42(15):1166-1180. [Abstract]
- Apoptosis. 2024 Oct;29(9-10):1499-1514. [Abstract]
- Int J Nanomedicine. 2018 Nov 13:13:7409-7426. [Abstract]
- Antioxidants (Basel). 2024 Aug 7;13(8):958. [Abstract]
- Phytother Res. 2026 Jun 18. [Abstract]
- Clin Transl Med. 2025 Jun;15(6):e70361. [Abstract]
- Clin Transl Med. 2023 Mar;13(3):e1213. [Abstract]
- Cell Rep. 2026 May 28;45(6):117471. [Abstract]
- Anal Chem. 2025 Jun 3;97(21):11099-11109. [Abstract]
- Clin Sci. 2021 Mar 26;135(6):793-810. [Abstract]
- Cell Mol Life Sci. 2025 Nov 13;82(1):396. [Abstract]
- Colloids Surf B Biointerfaces. 2025 Nov 25:259:115314. [Abstract]
- Eur J Pharmacol. 2025 Dec 15:1009:178390. [Abstract]
- Int Immunopharmacol. 2025 Sep 23:162:115168. [Abstract]
- Int Immunopharmacol. 2024 Sep 30:139:112707. [Abstract]
- Int Immunopharmacol. 2023 Oct:123:110761. [Abstract]
- Biomolecules. 2023 Apr 25;13(5):740. [Abstract]
- Int J Mol Sci. 2023 Feb 3;24(3):2960. [Abstract]
- Biomolecules. 2022 Nov 25;12(12):1754. [Abstract]
- Chem Biol Interact. 2023 Sep 1:382:110636. [Abstract]
- J Mol Cell Cardiol. 2025 May:202:133-143. [Abstract]
- Sci Rep. 2019 Dec 19;9(1):19450. [Abstract]
- J Physiol. 2024 Jan;602(2):317-332. [Abstract]
- FASEB J. 2025 Jul 15;39(13):e70761. [Abstract]
- Front Physiol. 2020 Sep 8:11:560170. [Abstract]
- FASEB J. 2019 May;33(5):6254-6268. [Abstract]
- FASEB J. 2018 Sep;32(9):5051-5062. [Abstract]
- Am J Physiol Heart Circ Physiol. 2018 Mar 1;314(3):H580-H592. [Abstract]
- J Orthop Surg Res. 2024 Feb 19;19(1):147. [Abstract]
- Toxicol Appl Pharmacol. 2026 Mar 27:511:117802. [Abstract]
- Toxicol Appl Pharmacol. 2024 May:486:116945. [Abstract]
- Am J Physiol Renal Physiol. 2020 Nov 1;319(5):F941-F953. [Abstract]
- J Appl Toxicol. 2026 Jun 17. [Abstract]
- Kaohsiung J Med Sci. 2025 Nov 28:e70144. [Abstract]
- Toxicol Lett. 2025 Apr:406:31-37. [Abstract]
- J Pharmacol Sci. 2020 Sep;144(1):30-42. [Abstract]
- Gene. 2022 Apr 30:820:146239. [Abstract]
- Biochem Biophys Res Commun. 2025 Jan:745:151256. [Abstract]
- Nefrologia. 2023 Sep 6.
- Rep Biochem Mol Biol. 2021 Jul;10(2):314-326. [Abstract]
- Arch Biol Sci. 2021 Jun.
- bioRxiv. 2026 Jun 19.
- bioRxiv. 2026 Jun 8:2026.06.03.729868. [Abstract]
- bioRxiv. 2026 Apr 7.
- SSRN. 2025 Nov 6.
- Res Sq. 2024 Jul 16.
- Friedrich-Alexander University Erlangen-Nuremberg. 2023 May 2.
- Research Square Print. September 13th, 2022.
- Oxid Med Cell Longev. 2022 Feb 18:2022:5044046. [Abstract]
Customer Validation & Images
-
In Vivo Efficacy Study
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
Cell Proliferation/Viability Assay
-
Apoptosis Analysis
Voir tous les produits spécifiques à Isoform Angiotensin Receptor
More
Activité biologique
Description
IC50 & Target
|
AT1 Receptor |
In Vitro
Losartan competes with the binding of angiotensin II to AT1 receptors. The concentration that inhibits 50% of the binding of angiotensin II (IC50) is 20 nM[1]. Losartan (40 μM) affects ISC but prevents the effect of ANGII on ISC[2]. Losartan significantly reduces Ang II-mediated cell proliferation in endometrial cancer cells. The combination of losartan and anti-miR-155 has a significantly greater antiproliferative effect compared to each drug alone[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 124750-99-8
-
Appearance Solid
-
Masse moléculaire 461.00
-
Formule C22H22ClKN6O
-
Color White to off-white
-
SMILES
OCC1=C(Cl)N=C(CCCC)N1CC2=CC=C(C3=CC=CC=C3C4=N[N-]N=N4)C=C2.[K+]
-
Synonyms
DuP-753 potassium
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
Publications (60)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
FGF4-FGFR1 signaling promotes podocyte survival and glomerular function to ameliorate diabetic kidney disease in male mice. [Abstract]2025 Nov 25;16(1):10430. PMID: 41290710
Losartan potassium purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 25;16(1):10430. [Abstract]
Blood glucose levels were significantly reduced in EMP-treated mice but remained unchanged with Losartan potassium (LOS, oral, 10 mg/kg/day) treatment.
-
Adv Sci (Weinh)
Targeted SPP1 Inhibition of Tumor-Associated Myeloid Cells Effectively Decreases Tumor Sizes. [Abstract]2025 Jan;12(4):e2410360. PMID: 39639496 -
Mol Biomed
2025 Feb 11;6(1):10. PMID: 39932642 -
Cell Death Dis
Sodium-glucose cotransporter 2 inhibition suppresses HIF-1α-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice. [Abstract]2020 May 22;11(5):390. PMID: 32444604
Losartan potassium purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2020 May 22;11(5):390. [Abstract]
Both dapagliflozin and Losartan potassium treatment significantly reduced the urinary albumin levels at 12 weeks.
Losartan potassium purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2020 May 22;11(5):390. [Abstract]
Both dapagliflozin and Losartan potassium treatment significantly reduced the NGAL levels at 12 weeks.
Losartan potassium purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2020 May 22;11(5):390. [Abstract]
Morphological analysis revealed that glomerular tuft area , mesangial expansion, and mesangial matrix hyperplasia (fractional mesangial area, FMA), which were increased in diabetic mice, were also equally improved by dapagliflozin and Losartan potassium treatment.
-
J Immunother Cancer
Telmisartan increases olaparib efficacy in homologous recombination proficient tumors by augmenting type I interferon production. [Abstract]2026 Mar 25;14(3):e012426. PMID: 41881499 -
J Immunother Cancer
Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade. [Abstract]2024 Sep 6;12(9):e009327. PMID: 39244215
Losartan potassium purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Sep 6;12(9):e009327. [Abstract]
Proliferation ability of MDA-MB-231 and HS578T cells in control and Losartan (10µM)-treated groups was assessed by colony formation assay.
Losartan potassium purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Sep 6;12(9):e009327. [Abstract]
Apoptosis level of MDA-MB-231 and HS578T cells in control and Losartan (10µM)-treated groups was assessed by flow cytometry assay.
Losartan potassium purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Sep 6;12(9):e009327. [Abstract]
Migration ability of MDA-MB-231 and HS578T cells in control and Losartan (10µM)-treated groups were assessed by Boyden chamber assay.
Losartan potassium purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Sep 6;12(9):e009327. [Abstract]
Expression of COL1A1 in control and Losartan (10µM)-treated CAFs was assessed by qPCR and Western blotting assays.
Losartan potassium purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Sep 6;12(9):e009327. [Abstract]
Expression of COL1A1 in control and Losartan (10µM)-treated CAFs was assessed by immunofluorescence assay.
-
Phytomedicine
Phillygenin improves diabetic nephropathy by inhibiting inflammation and apoptosis via regulating TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β signaling pathways. [Abstract]2025 Jan:136:156314. PMID: 39647467
Losartan potassium purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Jan:136:156314. [Abstract]
The CCK-8 assay was performed to determine cell viability after Losartan potassium treatment under HG conditions for 48 h.
Losartan potassium purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Jan:136:156314. [Abstract]
The kidney/body weight ratios demonstrated that both Losartan potassium and PHI exerted nephroprotective effects against DN, with H-PHI treatment exhibiting a greater effect.
-
Phytomedicine
Rutin alleviates EndMT by restoring autophagy through inhibiting HDAC1 via PI3K/AKT/mTOR pathway in diabetic kidney disease. [Abstract]2023 Apr:112:154700. PMID: 36774842 -
Phytomedicine
2022 Mar 21;100:154067. PMID: 35349832 -
Adv Healthc Mater
Cascade-Responsive Nanoprodrug Disrupts Immune-Fibroblast Communications for Potentiated Cancer Mechanoimmunotherapy. [Abstract]2025 Apr;14(11):e2500176. PMID: 40079115 -
J Transl Med
(Pro)renin receptor mediates tubular epithelial cell pyroptosis in diabetic kidney disease via DPP4-JNK pathway. [Abstract]2024 Jan 5;22(1):26. PMID: 38183100 -
Oncogene
Stromal nicotinamide N-methyltransferase orchestrates the crosstalk between fibroblasts and tumour cells in oral squamous cell carcinoma: evidence from patient-derived assembled organoids. [Abstract]2023 Apr;42(15):1166-1180. PMID: 36823377 -
Apoptosis
Targeting PAX8 sensitizes ovarian cancer cells to ferroptosis by inhibiting glutathione synthesis. [Abstract]2024 Oct;29(9-10):1499-1514. PMID: 38853202 -
Int J Nanomedicine
Peritumoral implantation of hydrogel-containing nanoparticles and losartan for enhanced nanoparticle penetration and antitumor effect. [Abstract]2018 Nov 13:13:7409-7426. PMID: 30519023 -
Antioxidants (Basel)
Identification and Validation of the miR/RAS/RUNX2 Autophagy Regulatory Network in AngII-Induced Hypertensive Nephropathy in MPC5 Cells Treated with Hydrogen Sulfide Donors. [Abstract]2024 Aug 7;13(8):958. PMID: 39199205 -
Phytother Res
Trilobatin Ameliorates Myocardial Hypertrophy by Enhancing Mitophagy Through Activation of the Sentrin-Specific Protease 1/Sirtuin 3 Axis in Spontaneously Hypertensive Rats. [Abstract]2026 Jun 18. PMID: 42316507 -
Clin Transl Med
DDR2-mediated autophagy inhibition contributes to angiotensin II-induced adventitial remodeling. [Abstract]2025 Jun;15(6):e70361. PMID: 40468620 -
Clin Transl Med
Angiotensin receptor blockers retard the progression and fibrosis via inhibiting the viability of AGTR1+ CAFs in intrahepatic cholangiocarcinoma. [Abstract]2023 Mar;13(3):e1213. PMID: 36855786 -
Cell Rep
2026 May 28;45(6):117471. PMID: 42213774 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
Clin Sci
Soluble (pro)renin receptor induces endothelial dysfunction and hypertension in mice with diet-induced obesity via activation of angiotensin II type 1 receptor. [Abstract]2021 Mar 26;135(6):793-810. PMID: 33625485 -
Cell Mol Life Sci
Rab26 promotes hypoxia-induced hyperproliferation of PASMCs by modulating the AT1R-STAT3-YAP axis. [Abstract]2025 Nov 13;82(1):396. PMID: 41231254 -
Colloids Surf B Biointerfaces
A losartan-laden thermosensitive hydrogel scaffold to boost tumor chemo-immunotherapy via remodeling tumor mechanical microenvironment. [Abstract]2025 Nov 25:259:115314. PMID: 41319609 -
Eur J Pharmacol
Angiotensin II-induced fibrosis is mediated by activation of FGFR1 pathway in renal epithelial cells: Attenuation by chimeric peptide. [Abstract]2025 Dec 15:1009:178390. PMID: 41274591 -
Int Immunopharmacol
ADAM17 knockdown is more effective than AT1R blocker in alleviating diabetic cardiomyopathy through downregulating the RhoA-ROCK1 pathway. [Abstract]2025 Sep 23:162:115168. PMID: 40633210 -
Int Immunopharmacol
Anti-tumor effects of telmisartan in glioma-astrocyte non-contact co-cultures: A critical role of astrocytic IL-6-mediated paracrine growth promotion. [Abstract]2024 Sep 30:139:112707. PMID: 39032472 -
Int Immunopharmacol
Telmisartan inhibits microglia-induced neurotoxic A1 astrocyte conversion via PPARγ-mediated NF-κB/p65 degradation. [Abstract]2023 Oct:123:110761. PMID: 37544025 -
Biomolecules
Trametinib-Induced Epidermal Thinning Accelerates a Mouse Model of Junctional Epidermolysis Bullosa. [Abstract]2023 Apr 25;13(5):740. PMID: 37238610 -
Int J Mol Sci
2023 Feb 3;24(3):2960. PMID: 36769281 -
Biomolecules
Structure-Based Virtual Screening and Functional Validation of Potential Hit Molecules Targeting the SARS-CoV-2 Main Protease. [Abstract]2022 Nov 25;12(12):1754. PMID: 36551182 -
Chem Biol Interact
Inhibition of AT1R/IP3/IP3R-mediated Ca2+ release protects against calcium oxalate crystals-induced renal oxidative stress. [Abstract]2023 Sep 1:382:110636. PMID: 37454925 -
J Mol Cell Cardiol
Elevated KCa3.1 expression by angiotensin II via the ERK/NF-κB pathway contributes to atrial fibrosis. [Abstract]2025 May:202:133-143. PMID: 40122157 -
Sci Rep
AT1 and AT2 receptors modulate renal tubular cell necroptosis in angiotensin II-infused renal injury mice. [Abstract]2019 Dec 19;9(1):19450. PMID: 31857626 -
J Physiol
miR-22-3p in the rostral ventrolateral medulla promotes hypertension through inhibiting β-arrestin-1. [Abstract]2024 Jan;602(2):317-332. PMID: 38152023 -
FASEB J
Mitochondrial Calcium Uniporter-Mediated Regulation of the SIRT3/GSK3β/β-Catenin Signaling Pathway in Vascular Remodeling. [Abstract]2025 Jul 15;39(13):e70761. PMID: 40622073 -
Front Physiol
Angiotensin II Stimulates the Proliferation and Migration of Lymphatic Endothelial Cells Through Angiotensin Type 1 Receptors. [Abstract]2020 Sep 8:11:560170. PMID: 33013481 -
FASEB J
Transactivation domain of Krüppel-like factor 15 negatively regulates angiotensin II-induced adventitial inflammation and fibrosis. [Abstract]2019 May;33(5):6254-6268. PMID: 30776250 -
FASEB J
Angiotensin II increases angiogenesis by NF-κB-mediated transcriptional activation of angiogenic factor AGGF1. [Abstract]2018 Sep;32(9):5051-5062. PMID: 29641288
Losartan potassium purchased from MedChemExpress. Usage Cited in: FASEB J. 2018 Sep;32(9):5051-5062. [Abstract]
HUVECs are starved for 12 h, treated with 10 mg/mL (9.56 μM) of AngII with or without Losartan or PD123319 for 12 h, and are subsequently used for Western blot analysis.
-
Am J Physiol Heart Circ Physiol
Overexpression of the neuronal human (pro)renin receptor mediates angiotensin II-independent blood pressure regulation in the central nervous system. [Abstract]2018 Mar 1;314(3):H580-H592. PMID: 29350998 -
J Orthop Surg Res
Several first-line anti-hypertensives act on fibrosarcoma progression and PD1ab blockade therapy. [Abstract]2024 Feb 19;19(1):147. PMID: 38373964 -
Toxicol Appl Pharmacol
Saikosaponin D protects against isoproterenol-induced kidney injury in rats by regulating the intrarenal renin-angiotensin system. [Abstract]2026 Mar 27:511:117802. PMID: 41903810 -
Toxicol Appl Pharmacol
In silico and in vitro assessment of drugs potentially causing adverse effects by inhibiting CYP17A1. [Abstract]2024 May:486:116945. PMID: 38688424 -
Am J Physiol Renal Physiol
Soluble (pro)renin receptor promotes the fibrotic response in renal proximal tubule epithelial cells in vitro via the Akt/β-catenin/Snail signaling pathway. [Abstract]2020 Nov 1;319(5):F941-F953. PMID: 32865015 -
J Appl Toxicol
The Angiotensin II Receptor Antagonist Losartan Impairs Female Fertility in Rats: Potential Mediating Role of microRNA-129-1-3p. [Abstract]2026 Jun 17. PMID: 42310910 -
Kaohsiung J Med Sci
Forsythiaside A Alleviates Kidney Injury and Intestinal Epithelium Dysfunction in IgA Nephropathy by Inhibiting TLR4/NF-κB Signaling. [Abstract]2025 Nov 28:e70144. PMID: 41313694 -
Toxicol Lett
Discovery of non-steroidal aldo-keto reductase 1D1 inhibitors through automated screening and in vitro evaluation. [Abstract]2025 Apr:406:31-37. PMID: 39988211 -
J Pharmacol Sci
Sustained increased CaMKII phosphorylation is involved in the impaired regression of isoproterenol-induced cardiac hypertrophy in rats. [Abstract]2020 Sep;144(1):30-42. PMID: 32665128 -
Gene
Calcitriol ameliorates renal injury with high-salt diet-induced hypertension by upregulating GLIS2 expression and AMPK/mTOR-regulated autophagy. [Abstract]2022 Apr 30:820:146239. PMID: 35114278 -
Biochem Biophys Res Commun
2025 Jan:745:151256. PMID: 39740402 -
-
Rep Biochem Mol Biol
Signaling Pathway in the Osmotic Resistance Induced by Angiotensin II AT2 Receptor Activation in Human Erythrocytes. [Abstract]2021 Jul;10(2):314-326. PMID: 34604421 -
-
-
bioRxiv
Angiotensin AT1 Receptors Promote Age-Dependent Expansion of Presympathetic Networks in Spontaneously Hypertensive Rats. [Abstract]2026 Jun 8:2026.06.03.729868. PMID: 42327208 -
-
-
-
-
-
Oxid Med Cell Longev
Angiotensin II Induces Cardiac Edema and Hypertrophic Remodeling through Lymphatic-Dependent Mechanisms. [Abstract]2022 Feb 18:2022:5044046. PMID: 35222798
Solvant et solubilité
In Vitro:
DMSO : ≥ 110 mg/mL (238.61 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 50 mg/mL (108.46 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (216.92 mM); Clear solution; Need ultrasonic
Protocole
Cell Assay[3]
An MTT assay is used to measure cell proliferation and viability. For the assay, 5000 cells in 200 μL media per well are seeded in a 96 well plate. After overnight incubation to allow for cell attachment, the medium is removed by suction. MTT at 1 mg/mL concentration in serum-free medium is added and then incubated for 4 h at 37°C. After removal of MTT solution, 100 μL of DMSO is added to dissolve formazan crystals. Absorbance at 570 nm and at 600 nm as a reference is then measured using a microplate reader. The difference in absorbance is thus relative to the extent of cell survival.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration[4]
Female Fbn1C1039G/+ mice undergo timed matings with wild-type male mice. At 14.5d post-coitum, pregnant female Fbn1C1039G/+ mice are treated with oral losartan (0.6 g/L in drinking water; n=10), propranolol (0.5 g/L; n=6) or placebo (n=12). Therapy is continued throughout lactation and after weaning until 10 months of age. Mice are sacrificed and examined using the techniques described above. Propranolol is used for comparison with losartan because β-adrenergic receptor blockade is the current albeit controversial standard of care to modulate abnormal growth of the aortic root in MFS. Beginning at 7 weeks of age, wild-type and Fbn1C1039G/+ mice are treated with oral losartan (0.6 g/L in drinking water; n=5), propranolol (0.5 g/L; n=7) or placebo (n=10). Mice are continued on oral therapy for 6 months and then sacrificed.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (285 KB)
-
SDS (604 KB)
- English - EN (604 KB)
- Français - FR (604 KB)
- Deutsch - DE (604 KB)
- Norwegian - NO (604 KB)
- Español - ES (604 KB)
- Swedish - SV (604 KB)
- Italian - IT (604 KB)
- Korean - KR (604 KB)
- Portuguese - PT (604 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Burnier, M. Angiotensin II type 1 receptor blockers. Circulation, 2001. 103(6): p. 904-12. [Content Brief]
[2]. Ashry, O., et al. Evidence for expression and function of angiotensin II receptor type 1 in pulmonary epithelial cells. Respir Physiol Neurobiol, 2014. [Content Brief]
[3]. Choi, C.H., et al. Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells. Gynecol Oncol, 2012. 126(1): p. 124-31. [Content Brief]
[4]. Habashi, J.P., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science, 2006. 312(5770): p. 117-21. [Content Brief]
[5]. Campbell, D.J., et al. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol, 1995. 26(2): p. 233-40. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.1692 mL | 10.8460 mL | 21.6920 mL | 54.2299 mL |
| 5 mM | 0.4338 mL | 2.1692 mL | 4.3384 mL | 10.8460 mL | |
| 10 mM | 0.2169 mL | 1.0846 mL | 2.1692 mL | 5.4230 mL | |
| 15 mM | 0.1446 mL | 0.7231 mL | 1.4461 mL | 3.6153 mL | |
| 20 mM | 0.1085 mL | 0.5423 mL | 1.0846 mL | 2.7115 mL | |
| 25 mM | 0.0868 mL | 0.4338 mL | 0.8677 mL | 2.1692 mL | |
| 30 mM | 0.0723 mL | 0.3615 mL | 0.7231 mL | 1.8077 mL | |
| 40 mM | 0.0542 mL | 0.2711 mL | 0.5423 mL | 1.3557 mL | |
| 50 mM | 0.0434 mL | 0.2169 mL | 0.4338 mL | 1.0846 mL | |
| 60 mM | 0.0362 mL | 0.1808 mL | 0.3615 mL | 0.9038 mL | |
| 80 mM | 0.0271 mL | 0.1356 mL | 0.2711 mL | 0.6779 mL | |
| 100 mM | 0.0217 mL | 0.1085 mL | 0.2169 mL | 0.5423 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Losartan potassium Related Classifications
HY-17512A Related Classifications
Powered by Bioz